Skip to main content

Coronavirus Infections

3
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 3 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

EMS
EMSBrazil - Hortolândia
2 programs
2
Hydroxychloroquine + azithromycinPhase 31 trial
Hydroxychloroquine Oral ProductPhase 31 trial
Active Trials
NCT04321278Completed440Est. Jun 2020
NCT04322123Completed667Est. Jun 2020
RedHill Biopharma
RedHill BiopharmaIsrael - Tel Aviv
1 program
1
OpaganibPhase 2Small Molecule1 trial
Active Trials
NCT04414618Completed42Est. Dec 2020
Rhythm Pharmaceuticals
1 program
Patients received standard of care treatment during hospitalizationN/A1 trial
Active Trials
NCT04465552Completed666Est. Jan 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EMSHydroxychloroquine Oral Product
EMSHydroxychloroquine + azithromycin
RedHill BiopharmaOpaganib
Rhythm PharmaceuticalsPatients received standard of care treatment during hospitalization

Clinical Trials (4)

Total enrollment: 1,815 patients across 4 trials

NCT04322123EMSHydroxychloroquine Oral Product

Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)

Start: Apr 2020Est. completion: Jun 2020667 patients
Phase 3Completed
NCT04321278EMSHydroxychloroquine + azithromycin

Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)

Start: Mar 2020Est. completion: Jun 2020440 patients
Phase 3Completed
NCT04414618RedHill BiopharmaOpaganib

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

Start: Jul 2020Est. completion: Dec 202042 patients
Phase 2Completed
NCT04465552Rhythm PharmaceuticalsPatients received standard of care treatment during hospitalization

Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients

Start: Jul 2020Est. completion: Jan 2021666 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.